Survodutide promotes weight loss in adults with obesity

In patients with obesity but without diabetes, treatment with survodutide results in substantial reductions in body weight compared with placebo, according to the phase III SYNCHRONIZE-1 trial.

SYNCHRONIZE-1 included 725 adult participants (mean age was 47.1 years, 40.6 percent male) with a BMI of ≥30 or ≥27 kg/m² plus at least one obesity-related complication (excluding diabetes). These participants were randomly assigned to receive survodutide administered subcutaneously once weekly at a dose adjusted up to 3.6 mg (n=241) or 6 mg (n=242) or placebo (n=242), in addition to counselling for lifestyle modification.

The two primary endpoints were the percent change in body weight and a reduction in body weight of ≥5 percent from baseline to week 76.

At baseline, the mean BMI overall was 37.9 kg/m², and the mean body weight was 108.8 kg. Over 76 weeks of treatment, mean body weight decreased by 12.2 percent with survodutide 3.6 mg, by 13 percent with survodutide 6 mg, and by 5.4 percent with placebo. The corresponding percentages of participants who lost at least 5 percent of their body weight were 72.6 percent, 71.9 percent, and 46.3 percent (p<0.001 for all).

As for safety, the most common adverse events were gastrointestinal symptoms, occurring in 80.9 percent of the participants in the 3.6-mg group, 89.7 percent of those in the 6-mg group, and 47.9 percent of those in the placebo group. Most of these events were mild to moderate in severity. There were no deaths reported during the trial.